





Supp. Fig. S1




Supp. Fig. S1. pGSN levels are not affected by gender and age. The mean \pm SEM levels of pGSN were compared between (A) male and female COVID-19 patients as well as (B) age ranges. (C-G) The mean \pm SEM levels of pGSN were also compared between days of sample collection. *P*-values were calculated using one-way ANOVA and independent sample *t*-test.

Supp. Fig. S2




Supp. Fig. S2. pGSN multi-analyte panels for monitoring disease severity and outcomes days from symptoms onset. pGSN, pGSN/HGF, pGSN/IP-10, pGSN/IgM and pGSN/IgG were utilized to monitor (A) disease severity, (B) discharge and (C) ICU admittance following day 1 from symptoms onset. *P*-values were calculated by one-way ANOVA and independent sample *t*-test.

Supp. Fig. S3




Supp. Fig. S3. Correlation between pGSN and SARS-CoV-2 antibodies. pGSN and SARS-CoV-2 antibodies (IgG, IgM and IgA) were assessed on day 0, 4 and 12 and correlated using Pearson's test.

Supp. Fig. S4



Supp. Fig. S4. pGSN multi-analyte panels as predictors of COVID-19 outcomes. ROC curves were used to assess the test performances of pGSN, CRP, platelets, D-dimer and Ferritin in predicting (A) severe COVID-19, (B) deceased patients, (C) mild COVID-19 cases, (D) ICU admissions and (E) patients that are discharged.

Supp. Fig. 5



Supp. Fig. S4. Multi-analyte panels predict more than one clinical outcomes of COVID-19. pGSN/IP-10, pGSN/HGF, pGSN/M-CSF, CRP, platelets, Ferritin and pGSN/IgG were used in a heat map analyses to predict (A) disease severity and hospitalization outcomes, (B) ICU admissions and hospitalization outcomes and (C) disease severity and ICU admissions.

Table 1: Demographics and Baseline Characteristics of COVID-19 Patients

| | | COVID-19 | | Non-COVID-19 | |
|---|---------------------|----------|-------|--------------|-------|
| | | Count | Mean | Count | Mean |
| Hospitalization outcomes at the end of follow-up | Deceased | 7 | | 0 | |
| | Discharged | 21 | | 0 | |
| BMI (Kg/m2) | | | 30.51 | | . |
| ICU Admittance | No | 23 | | 0 | |
| | Yes | 5 | | 0 | |
| Age (yrs) | | | 63.93 | | 41.67 |
| Gender | Female | 6 | | 7 | |
| | Male | 22 | | 5 | |
| COVID Disease Severity | No infection | 0 | | 12 | |
| | Mild | 7 | | 0 | |
| | Moderate | 18 | | 0 | |
| | Severe | 3 | | 0 | |
| | 2 | 2 | | 0 | |
| Days from first positive COVID-19 Test | 3 | 7 | | 0 | |
| | 4 | 4 | | 0 | |
| | 5 | 1 | | 0 | |
| | 6 | 1 | | 0 | |
| | 7 | 4 | | 0 | |
| | 8 | 1 | | 0 | |
| | 9 | 2 | | 0 | |
| | 11 | 1 | | 0 | |
| | 13 | 1 | | 0 | |
| | 14 | 1 | | 0 | |
| | 15 | 1 | | 0 | |
| | 17 | 1 | | 0 | |
| | 20 | 1 | | 0 | |
| Days from symptom onset | 3 | 1 | | 0 | |
| | 4 | 2 | | 0 | |
| | 5 | 1 | | 0 | |
| | 6 | 1 | | 0 | |
| | 7 | 3 | | 0 | |
| | 8 | 2 | | 0 | |
| | 9 | 4 | | 0 | |
| | 11 | 4 | | 0 | |
| | 12 | 2 | | 0 | |
| | 13 | 2 | | 0 | |
| | 15 | 1 | | 0 | |
| | 16 | 3 | | 0 | |
| | 20 | 1 | | 0 | |
| | 22 | 1 | | 0 | |

Disease severity was defined as follows:

1. Mild (no oxygen/room air received)
2. Moderate [supplemental oxygen, not high flow or no flow listed, no intubation/mechanical ventilation – ex. No Bi-level Positive Airway Pressure (BiPap) /intubation)].
3. Severe (high flow oxygen and non-invasive or invasive mechanical ventilation – ex. Yes BiPap/intubation)